Amplification of mutant <em>KRAS</em><sup>G12D</sup> in a patient with advanced metastatic pancreatic adenocarcinoma detected by liquid biopsy: A case report

Pittella‑Silva,Fabio; Kimura,Yasutoshi; Low,Siew-Kee; Nakamura,Yusuke; Motoya,Masayo

doi:10.3892/mco.2021.2334

Amplification of mutant KRAS^G12D in a patient with advanced metastatic pancreatic adenocarcinoma detected by liquid biopsy: A case report

Authors:
- Fabio Pittella‑Silva
- Yasutoshi Kimura
- Siew-Kee Low
- Yusuke Nakamura
- Masayo Motoya
View Affiliations

Affiliations: Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo 135‑8550, Japan, Department of Surgery, Surgical Oncology and Science, Sapporo Medical University School of Medicine, Sapporo 060‑8543, Japan, Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo 060‑8543, Japan
Published online on: June 29, 2021 https://doi.org/10.3892/mco.2021.2334
Article Number: 172
Copyright: © Pittella‑Silva et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancer types. Activating oncogenic KRAS mutations are commonly observed in PDAC; however, oncogenic KRAS amplification is rarely observed, and its significance in prognosis and resistance to therapy remains poorly characterized. The present report describes the case of a 52‑year‑old male patient diagnosed with advanced PDAC with liver metastasis. The patient received modified FOLFIRINOX (mFFX) therapy to which the patient became intolerant with a strong inflammatory response. Subsequent treatment with gemcitabine plus nab‑paclitaxel failed to control the disease. Targeted genetic analysis revealed KRAS^G12D and TP53^R248Q mutations in the primary tumor and liver metastases. Analysis of circulating tumor DNA (ctDNA) before the first line of treatment confirmed these genetic findings and revealed a >4‑fold amplification of the mutant KRAS^G12D not detected in the primary tumor. Additionally, subsequent analysis confirmed a 5‑fold amplification of the KRASG12D allele in liver metastasis. Consecutive monitoring of ctDNA revealed an initial decrease in the tumor burden 2 weeks after the first cycle of mFFX. However, coinciding with treatment intolerance, a sharp increase in tumor mutational levels and KRAS^G12D amplification was observed 1 month later. The patient died 70 days after treatment initiation. Overall, amplification of oncogenic KRAS^G12D was not only associated with an aggressive phenotype, but also supported cancer resistance to chemotherapy. Importantly, this case suggests that plasma detection of KRAS^G12D amplification is feasible in the clinical routine and constitutes a powerful tool for assessing tumor aggressiveness.

View Figures

View References

1	Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74:2913–2921. 2014.PubMed/NCBI View Article : Google Scholar
2	Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T, et al: Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 26 (Suppl 5):v56–v68. 2015.PubMed/NCBI View Article : Google Scholar
3	Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, et al: Adjuvant chemotherapy with fluorouracil plus folinic acid vs. gemcitabine following pancreatic cancer resection: A randomized controlled trial. JAMA. 304:1073–1081. 2010.PubMed/NCBI View Article : Google Scholar
4	Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, et al: Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: A phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 388:248–257. 2016.PubMed/NCBI View Article : Google Scholar
5	Sinn M, Bahra M, Liersch T, Gellert K, Messmann H, Bechstein W, Waldschmidt D, Jacobasch L, Wilhelm M, Rau BM, et al: CONKO-005: Adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: A multicenter randomized phase III trial. J Clin Oncol. 35:3330–3337. 2017.PubMed/NCBI View Article : Google Scholar
6	Gbolahan OB, Tong Y, Sehdev A, O'Neil B and Shahda S: Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: A retrospective study. BMC Cancer. 19(468)2019.PubMed/NCBI View Article : Google Scholar
7	Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, et al: Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 518:495–501. 2015.PubMed/NCBI View Article : Google Scholar
8	Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S, Mercer KL, Grochow R, Hock H, Crowley D, et al: Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell. 5:375–387. 2004.PubMed/NCBI View Article : Google Scholar
9	Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff JL, et al: Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 149:656–670. 2012.PubMed/NCBI View Article : Google Scholar
10	Junttila MR, Karnezis AN, Garcia D, Madriles F, Kortlever RM, Rostker F, Brown Swigart LB, Pham DM, Seo Y, Evan GI and Martins CP: Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature. 468:567–571. 2010.PubMed/NCBI View Article : Google Scholar
11	Burgess MR, Hwang E, Mroue R, Bielski CM, Wandler AM, Huang BJ, Firestone AJ, Young A, Lacap JA, Crocker L, et al: KRAS Allelic imbalance enhances fitness and modulates MAP kinase dependence in cancer. Cell. 168:817–829.e15. 2017.PubMed/NCBI View Article : Google Scholar
12	Sobin LH, Gospodarowicz MK and Wittekind C (eds): International Union Against Cancer (UICC): TNM Classification of Malignant Tumours. 7th edition, Wiley-Blackwell, Oxford, 2009.
13	Okusaka T, Nakamura M, Yoshida M, Kitano M, Uesaka K, Ito Y, Furuse J, Hanada K and Okazaki K: Committee for Revision of Clinical Guidelines for Pancreatic Cancer of the Japan Pancreas Society. Clinical practice guidelines for pancreatic cancer 2019 from the Japan pancreas society: A synopsis. Pancreas. 49:326–335. 2020.PubMed/NCBI View Article : Google Scholar
14	Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et al: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 321:1801–1806. 2008.PubMed/NCBI View Article : Google Scholar
15	Sodir NM, Kortlever RM, Barthet VJA, Campos T, Pellegrinet L, Kupczak S, Anastasiou P, Swigart LB, Soucek L, Arends MJ, et al: MYC instructs and maintains pancreatic adenocarcinoma phenotype. Cancer Discov. 10:588–607. 2020.PubMed/NCBI View Article : Google Scholar
16	Mueller S, Engleitner T, Maresch R, Zukowska M, Lange S, Kaltenbacher T, Konukiewitz B, Öllinger R, Zwiebel M, Strong A, et al: Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature. 554:62–68. 2018.PubMed/NCBI View Article : Google Scholar
17	Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA, Rashid NU, Williams LA, Eaton SC, Chung AH, et al: Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 47:1168–1178. 2015.PubMed/NCBI View Article : Google Scholar